This is a preprint.
The conformational landscape of human transthyretin revealed by cryo-EM
- PMID: 38328110
- PMCID: PMC10849623
- DOI: 10.1101/2024.01.23.576879
The conformational landscape of human transthyretin revealed by cryo-EM
Update in
-
The conformational landscape of human transthyretin revealed by cryo-EM.Nat Struct Mol Biol. 2025 May;32(5):876-883. doi: 10.1038/s41594-024-01472-7. Epub 2025 Jan 22. Nat Struct Mol Biol. 2025. PMID: 39843982 Free PMC article.
Abstract
Transthyretin (TTR) is a natively tetrameric thyroxine transporter found in blood and cerebrospinal fluid whose misfolding and aggregation causes transthyretin amyloidosis. A rational drug design campaign identified the small molecule tafamidis (Vyndaqel/Vyndamax) as an effective stabilizer of the native TTR fold, and this aggregation inhibitor is regulatory agency-approved for the treatment of TTR amyloidosis. Despite 50 years of structural studies on TTR and this triumph of structure-based drug design, there remains a notable dearth of structural information available to understand ligand binding allostery and amyloidogenic TTR unfolding intermediates. We used single-particle cryo-electron microscopy (cryo-EM) to investigate the conformational landscape of this 55 kiloDalton tetramer in the absence and presence of one or two ligands, revealing inherent asymmetries in the tetrameric architecture and previously unobserved conformational states. These findings provide critical mechanistic insights into negatively cooperative ligand binding and the structural pathways responsible for TTR amyloidogenesis. This study underscores the capacity of cryo-EM to provide new insights into protein structures that have been historically considered too small to visualize and to identify pharmacological targets suppressed by the confines of the crystal lattice, opening uncharted territory in structure-based drug design.
Conflict of interest statement
Competing interests JWK and ETP discovered tafamidis and receive royalty payments for its sales. JWK was a founder and shareholder in FoldRx, which first developed tafamidis as a therapeutic. JWK is a paid consultant for and has received support for travel and accommodations from Pfizer, which sells tafamidis.
Figures




Similar articles
-
The conformational landscape of human transthyretin revealed by cryo-EM.Nat Struct Mol Biol. 2025 May;32(5):876-883. doi: 10.1038/s41594-024-01472-7. Epub 2025 Jan 22. Nat Struct Mol Biol. 2025. PMID: 39843982 Free PMC article.
-
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9629-34. doi: 10.1073/pnas.1121005109. Epub 2012 May 29. Proc Natl Acad Sci U S A. 2012. PMID: 22645360 Free PMC article.
-
Structural evidence for asymmetric ligand binding to transthyretin.Acta Crystallogr D Biol Crystallogr. 2015 Aug;71(Pt 8):1582-92. doi: 10.1107/S1399004715010585. Epub 2015 Jul 28. Acta Crystallogr D Biol Crystallogr. 2015. PMID: 26249340
-
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis.Neurol Ther. 2016 Jun;5(1):1-25. doi: 10.1007/s40120-016-0040-x. Epub 2016 Feb 19. Neurol Ther. 2016. PMID: 26894299 Free PMC article. Review.
-
Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses?Curr Med Chem. 2012;19(15):2324-42. doi: 10.2174/092986712800269335. Curr Med Chem. 2012. PMID: 22471981 Review.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous